B
Bob Löwenberg
Researcher at Erasmus University Medical Center
Publications - 610
Citations - 54872
Bob Löwenberg is an academic researcher from Erasmus University Medical Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 104, co-authored 594 publications receiving 48466 citations. Previous affiliations of Bob Löwenberg include Erasmus University Rotterdam & Laboratory of Molecular Biology.
Papers
More filters
Journal ArticleDOI
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner,Elihu H. Estey,David Grimwade,Sergio Amadori,Frederick R. Appelbaum,Thomas Büchner,Hervé Dombret,Benjamin L. Ebert,Pierre Fenaux,Richard A. Larson,Ross L. Levine,Francesco Lo-Coco,Tomoki Naoe,Dietger Niederwieser,Gert J. Ossenkoppele,Miguel A. Sanz,Jorge Sierra,Martin S. Tallman,Hwei-Fang Tien,Andrew H. Wei,Andrew H. Wei,Bob Löwenberg,Clara D. Bloomfield +22 more
TL;DR: An international panel to provide updated evidence- and expert opinion-based recommendations for diagnosis and management of acute myeloid leukemia in adults includes a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.
Journal ArticleDOI
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Hartmut Döhner,Elihu H. Estey,Sergio Amadori,Frederick R. Appelbaum,Thomas Büchner,Alan Kenneth Burnett,Hervé Dombret,Pierre Fenaux,David Grimwade,Richard A. Larson,Francesco Lo-Coco,Tomoki Naoe,Dietger Niederwieser,Gert J. Ossenkoppele,Miguel A. Sanz,Jorge Sierra,Martin S. Tallman,Bob Löwenberg,Clara D. Bloomfield +18 more
TL;DR: An international expert panel is provided to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials.
Journal ArticleDOI
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D. Cheson,John M. Bennett,Kenneth J. Kopecky,Thomas Büchner,Cheryl L. Willman,Elihu H. Estey,Charles A. Schiffer,Hartmut Doehner,Martin S. Tallman,T. Andrew Lister,Francesco Lo-Coco,Roel Willemze,Andrea Biondi,Wolfgang Hiddemann,Richard A. Larson,Bob Löwenberg,Miguel A. Sanz,David R. Head,Ryuzo Ohno,Clara D. Bloomfield +19 more
TL;DR: An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia originally published in 1990, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials as mentioned in this paper.
Journal ArticleDOI
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Maria E. Figueroa,Omar Abdel-Wahab,Chao Lu,Patrick S. Ward,Jay P. Patel,Alan Shih,Yushan Li,Neha Bhagwat,Aparna Vasanthakumar,Hugo F. Fernandez,Martin S. Tallman,Zhuoxin Sun,Kristy L. Wolniak,Justine K. Peeters,Wei Liu,Sung E. Choe,Valeria Fantin,Elisabeth Paietta,Bob Löwenberg,Jonathan D. Licht,Lucy A. Godley,Ruud Delwel,Peter J. M. Valk,Craig B. Thompson,Ross L. Levine,Ari Melnick +25 more
TL;DR: Mutational and epigenetic profiling of a large acute myeloid leukemia (AML) patient cohort revealed that IDH1/2-mutant AMLs display global DNA hypermethylation and a specificHypermethylation signature, suggesting a shared proleukemogenic effect.
Journal ArticleDOI
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson,Peter L. Greenberg,John M. Bennett,Bob Löwenberg,Pierre W. Wijermans,Stephen D. Nimer,Antonio Pinto,Miloslav Beran,Theo de Witte,Richard Stone,Moshe Mittelman,Guillermo Sanz,Steven D. Gore,Charles A. Schiffer,Hagop M. Kantarjian +14 more
TL;DR: Recommendations for revisions of some of the initial response criteria for evaluating clinically significant responses in myelodysplastic syndromes are presented.